Nantahala Capital Management LLC Takes $4.03 Million Position in DarioHealth Corp. $DRIO

Nantahala Capital Management LLC bought a new position in shares of DarioHealth Corp. (NASDAQ:DRIO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 610,691 shares of the company’s stock, valued at approximately $4,030,561. Nantahala Capital Management LLC owned about 8.32% of DarioHealth at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. Kestra Advisory Services LLC purchased a new stake in DarioHealth in the fourth quarter valued at $35,000. XTX Topco Ltd grew its position in DarioHealth by 229.0% during the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after purchasing an additional 43,513 shares during the period. BlackRock Inc. purchased a new position in shares of DarioHealth during the 2nd quarter valued at about $249,000. Finally, Geode Capital Management LLC raised its stake in shares of DarioHealth by 167.9% during the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock valued at $564,000 after buying an additional 31,063 shares during the last quarter. Hedge funds and other institutional investors own 33.39% of the company’s stock.

DarioHealth Stock Performance

DRIO opened at $6.77 on Friday. The firm has a market capitalization of $66.35 million, a PE ratio of -1.10 and a beta of 1.11. DarioHealth Corp. has a twelve month low of $5.84 and a twelve month high of $17.74. The firm’s 50-day moving average price is $7.09 and its 200 day moving average price is $7.99. The company has a current ratio of 2.31, a quick ratio of 1.92 and a debt-to-equity ratio of 0.56.

DarioHealth (NASDAQ:DRIO) last issued its earnings results on Tuesday, August 11th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.37. DarioHealth had a negative return on equity of 54.81% and a negative net margin of 169.87%.The company had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $5.92 million. As a group, sell-side analysts expect that DarioHealth Corp. will post -2.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on DRIO shares. Alliance Global Partners initiated coverage on shares of DarioHealth in a research note on Wednesday, August 19th. They set a “buy” rating and a $12.00 price objective on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of DarioHealth in a research note on Friday, July 10th. TD Cowen lowered their price target on shares of DarioHealth from $11.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday, August 12th. Finally, Stifel Nicolaus restated a “buy” rating and set a $10.00 price target on shares of DarioHealth in a research report on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $10.00.

Insider Buying and Selling at DarioHealth

In other news, Director Dennis Matheis purchased 14,430 shares of the stock in a transaction dated Thursday, July 23rd. The shares were purchased at an average price of $6.93 per share, with a total value of $99,999.90. Following the transaction, the director owned 43,026 shares in the company, valued at $298,170.18. The trade was a 50.46% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.50% of the company’s stock.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.